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case report forms and radiological response was assessed 
using the modified RANO criteria. Quality of life (QoL) 
was assessed using PedsQL questionnaires. Between June 
2012 and December 2016, nine patients were enrolled. 
Treatment was well tolerated, and no DLTs were observed 
up to the maximum dose of 200 mg/m2. All patients experi-
enced reduction of tumor-related symptoms. QoL tended to 
improve during treatment. PFS and MOS were 4.8 months 
(95% CI 4.0–5.7) and 8.7  months (95% CI 7.0–10.4). 
Classifying patients according to the recently developed 
DIPG survival prediction model, intermediate risk patients 
(n = 4), showed a PFS and MOS of 6.4 and 12.4 months, 
respectively, versus a PFS and MOS of 4.5 and 8.1 months, 
respectively, in high risk patient (n = 5). Gemcitabine up to 
200 mg/m2/once weekly, added to radiotherapy, is safe and 
well tolerated in children with newly diagnosed DIPG. PFS 
and MOS were not significantly different from literature.
Keywords Diffuse intrinsic pontine glioma (DIPG) · 
Radiotherapy · Radiosensitizer · Gemcitabine
Abstract The purpose of this phase I/II, open-label, 
single-arm trial is to investigate the safety, tolerability, 
maximum tolerated dose and preliminary efficacy of the 
potential radiosensitizer gemcitabine, administered con-
comitantly to radiotherapy, in children with newly diag-
nosed diffuse intrinsic pontine glioma (DIPG). Six doses of 
weekly gemcitabine were administered intravenously, con-
comitantly to 6  weeks of hyperfractionated radiotherapy. 
Successive cohorts received increasing doses of 140, 175 
and 200 mg/m2 gemcitabine, respectively, following a 3 + 3 
dose-escalation schedule without expansion cohort. Dose-
limiting toxicities (DLT) were monitored during treatment 
period. Clinical response was assessed using predefined 
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Introduction
Patients with diffuse intrinsic pontine glioma (DIPG) face a 
dismal prognosis, with less than 10% of the patients being 
alive at 2 years after initial diagnosis, and a median overall 
survival (MOS) of 9 months [1, 2]. To date, radiotherapy is 
the only effective, albeit palliative, treatment option, with 
temporary improvement of symptoms and a survival ben-
efit of approximately 3 months [3].
Gemcitabine, a pyrimidine antimetabolite of cytosine, 
has proven to penetrate the blood–brain–barrier (BBB) 
reaching radiosensitizing levels in adults with glioblastoma 
multiforme (GBM), when administered in single doses of 
500 or 1000 mg/m2 [4]. Furthermore, gemcitabine displays 
radiosensitizing effects at concentrations 1000 times lower 
than cytotoxic plasma levels [5]. The radiosensitizing doses 
in the current trial were based on studies by Fabi et al. [6] 
and Metro et  al. [7], showing a maximum tolerated dose 
(MTD) of 175 mg/m2 gemcitabine once weekly, concomi-
tant to radiotherapy in adult GBM [6, 7]. In children, gem-
citabine monotherapy has proven to be safe and tolerable 
up to cytotoxic dosages of 3600 mg/m2/week in leukemia, 
Hodgkin’s lymphoma and solid tumor patients [8–11]. Tox-
icities observed in these pediatric studies are mainly myel-
otoxicity, elevation of liver enzymes and mucositis. Since 
the present study aims for the radiosensitizing effect of 
gemcitabine, much lower doses were used, and only limited 
additional toxicity was not expected.
The purpose of this study is to (i) determine the safety 
and tolerability of adding the radiosensitizer gemcitabine, 
to standard radiotherapy in patients with newly diagnosed 
DIPG, using three pre-specified dose levels, (ii) explore the 
preliminary efficacy in terms of clinical and radiological 
response and to compare progression free survival (PFS) 
and MOS at these dose levels, and to (iii) evaluate the qual-
ity of life (QoL) during treatment.
Patients and methods
Approval
This study (EudraCT 2009-016080-11, Dutch Trial Reg-
ister NTR2391) was approved by the institutional review 
board of VU University Medical Center (METc VUmc, 
study number: VUMC2010/164), and the Scientific Com-
mittee of the Dutch Childhood Oncology Group (DCOG). 
The use of gemcitabine has been approved by U.S. Food 
and Drug Administration (FDA) and European Medicines 
Agency (EMA) for adults, and has been tested and proven 
to be safe in children up to 1000  mg/m2/dose (off-label) 
when combined with other chemotherapeutic drugs [12]. 
All parents signed informed consent, and patients between 
12 and 18 years of age also signed informed assent.
In‑ and exclusion criteria
Children aged 3–18  years with newly diagnosed DIPG 
were eligible for this study. Inclusion criteria were: (i) diag-
nosis of a typical DIPG: symptoms <6 months and MRI-
confirmed (≥50% involvement of the transverse area of the 
pons, T1 hypointensity, T2 hyperintensity, with a clear ori-
gin in the pons), (ii) written informed consent, (iii) trans-
fusion-independent platelet count ≥75 × 109/L, peripheral 
absolute neutrophil count (ANC) ≥0.75 × 109/L, (iv) ade-
quate liver function, defined as direct bilirubin ≤1.5 × upper 
limit of normal (ULN) for age and alanine aminotrans-
ferase (ALAT) <5 × upper limit of normal (ULN) for age, 
(v) adequate renal function, defined as serum creatinine 
≤1.5 × upper limit of normal (ULN) for age, (vi) willing-
ness to perform a pregnancy test and apply contraceptives 
in females of child-bearing age. Biopsy was offered as an 
option, but was not mandatory for the diagnosis of a DIPG. 
Exclusion criteria were: (i) clinically-diagnosed neurofi-
bromatosis (NF) type I (DNA-diagnostics not mandatory), 
(ii) patients who received prior therapeutic treatment for 
DIPG (except corticosteroids), (iii) presence of diffuse lep-
tomeningeal disease, (iv) performance status (Lansky or 
Karnofsky score) of 40 or less (v) contra-indications for 
chemotherapy.
Study objectives
The primary objective was to determine the safety and 
tolerability of gemcitabine at three pre-specified differ-
ent dose levels; 140, 175 and 200  mg/m2. The secondary 
objective was to evaluate the preliminary efficacy in terms 
of PFS and MOS at these dose levels. Progressive disease 
was defined as clinical signs of disease progression (i.e., 
increase of symptoms or new symptoms) and/or radiologi-
cal progression based on the modified RANO criteria. The 
tertiary objective was to evaluate the quality of life (QoL) 
using QoL questionnaires.
Study procedures
Patients received weekly gemcitabine, concomitant with 
6 weeks of radiotherapy: 54 Gy in 30 fractions of 1.8 Gy 
directed at the tumor using volumetric modulated arc ther-
apy (VMAT). The VMAT technique was used to reduce 
toxicity as much as possible. Gemcitabine was adminis-
tered intravenously once weekly for 6 weeks, starting 24 h 
before the first day of radiotherapy. This schedule was 
based on a previous gemcitabine and radiotherapy study [6, 
7]. Doses were escalated in successive patients following a 
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traditional 3 + 3 dose-escalation, without a dose expansion 
cohort [13]. If a dose limiting toxicity (DLT) was observed 
in one out of three patients in a specific cohort, three addi-
tional patients were enrolled in that cohort. The MTD was 
reached if more than one out of six patients (in 1 cohort) 
developed a DLT. In that case further dose escalation was 
not pursued. If no DLT was observed in any of the patients 
in a specific cohort at 2 weeks after gemcitabine adminis-
tration, additional trial patients were treated following the 
next higher dose cohort until the predefined highest dose 
of 200  mg/m2 was reached [13]. Following this method, 
a minimum of three and a maximum of 18 patients were 
expected to be included. The starting dose was 140  mg/
m2, which is 80% of the recommended dose of 175 mg/m2 
by Fabi et al. [6, 7]. Successive cohorts received doses of 
175, and 200 mg/m2 as the predefined highest dose. Gem-
citabine was reconstituted in 50 mL 0.9% sodium chloride 
solution and administered intravenously at a rate of 10 mg/
m2/min. Prior to each cycle of gemcitabine, patients were 
required to qualify based on hematological examination; 
the ANC had to be equal to or >0.75 × 109/L, and the plate-
let count equal to or >75 × 109/L. If required, ondansetron 
 (Zofran®) was administered intravenously before gem-
citabine administration or orally before radiotherapy. All 
patients were treated in one center, VU University Medical 
Center (VUMC) Amsterdam.
Safety assessments and response evaluation
A DLT was defined as any clinically relevant, and likely 
drug-related, grade ≥3 adverse event (AE), according to 
criteria outlined in the NCI Common Terminology Criteria 
for Adverse Events (CTCAE), version 4.0 [14]. Asympto-
matic laboratory abnormalities were not considered a DLT. 
DLTs were evaluated during the 6 weeks treatment period.
Safety assessments (i.e., evaluation of DLTs) included 
weekly examination of urine and blood (hemoglobin), 
platelets, white blood cell count and differentiation, cre-
atinine, blood urea nitrogen, uric acid, albumin, sodium, 
potassium, calcium, magnesium, phosphate, ASAT, ALAT, 
G-GT, bilirubin, LDH, bicarbonate, glucose, and extra 
collections according to the treating physician. Urine and 
blood were examined weekly during the 6-week treatment 
period. In case of abnormalities, safety assessments pro-
ceeded until aberrant values normalized.
Additionally, patients underwent regular full physical 
and neurological examination by either a pediatric oncolo-
gist or a child neurologist in order to assess possible DLTs 
and possible disease progression. This was performed 
once every 2 weeks during treatment to assess DLTs, and 
for disease progression once monthly until 3 months post-
treatment (i.e. week 19) or until disease progression. In 
case of stable disease after week 19, clinical follow-up was 
performed every 3 months to determine the PFS and MOS. 
Disease progression was defined as clinical signs of disease 
progression (i.e., increase of symptoms or new symptoms) 
and/or radiological tumor progression, whichever came 
first.
Radiologic response was evaluated by a neuro-radiol-
ogist using the modified RANO criteria, which takes into 
account the change in T1 gadolinium enhancement and T2 
tumor size, development of metastasis, use of corticoster-
oids and clinical status [15]. MR-scans of the brain and spi-
nal cord were performed at baseline, 3 months post-treat-
ment and/or at disease progression.
QoL was assessed at baseline, and 3 months post-treat-
ment by three categories of the PedsQL questionnaires 
(Pediatric Quality of Life Inventory TM [16, 17]): (i) the 
PedsQL TM 4.0 Generic Core Scales, addressing physi-
cal performance and psychosocial health, (ii) the PedsQL 
TM Multidimensional Fatigue Scale, addressing general 
fatigue, sleep rhythm and cognitive fatigue and (iii) the 
PedsQL TM 3.0 Cancer Module, addressing pain during 
treatment, nausea, fear of treatment and procedures, wor-
rying about disease course and appearances and communi-
cation with other people. PedsQL provides age-appropriate 
questionnaires that take approximately 10 min per category.
Supportive care
In the first week of radiotherapy, the use of dexamethasone 
was allowed in order to reduce symptoms related to edema 
formation. After the first week, physicians were encouraged 
to stop or taper dexamethasone as soon as possible because 
of associated side-effects [18] and possible negative effects 
on blood–brain–barrier penetrance and activity of gemcit-
abine [19, 20].
Statistical methods
Data were analyzed using IBM SPSS Statistics for Win-
dows, Version 22.0 (Armonk, NY: IBM Corp. Released 
2013). Patient data regarding demographics were ana-
lyzed by descriptive statistics. PFS and MOS were deter-
mined by means of Kaplan–Meier method. PFS and MOS 
of the total study cohort were compared to historical sur-
vival data of DIPG patients receiving “radiotherapy only” 
found in literature. Subsequently, each patient was classi-
fied in a risk-category according to the recently developed 
DIPG survival prediction model, to evaluate whether the 
risk-classification of the patients might have influenced the 
observed survival [21, 22].
For each patient, an individual risk-score was calcu-
lated based on the following formula: symptom duration 
(in months) at time of diagnosis (time minus one), added 
with seven points if age ≥3 years, added with four points 
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if ring enhancement is present on diagnostic MRI. Based 
on the risk-score, patients were categorized as being stand-
ard- (score ≤1), intermediate- (1–6) or high-risk (≥7). For 
each risk-group subgroup specific PFS and MOS were 
calculated, and compared to the survival data reported by 
Jansen et al. [21] QoL data before and after treatment were 
compared using the Wilcoxon signed ranks test. Statistical 
significance was defined as a 2-sided P < 0.05.
Results
Patients
Between June 2012 and December 2015, nine patients with 
newly diagnosed DIPG were included in this study. Patient 
data regarding demographics, clinical characteristics and 
diagnosis are summarized in Table 1. The median age was 
10.8 years (range 7.5–17.3). Signs of disease preceded the 
hospital presentation by a median time of 2 weeks. Symp-
toms most commonly observed were abducens nerve palsy, 
diplopia, impaired coordination and ataxia. None of the 
patients received any treatment prior to participating in this 
study. Based on the DIPG survival prediction model, four 
patients were intermediate- and five patients were high-risk 
patients, with scores varying from 6.0 to 10.75 [21].
Toxicity
All patients received radiotherapy up to a total dose of 
54  Gy following the predefined schedule of 30 fractions 
of 1.8  Gy. Cohort 1, 2 and 3, received gemcitabine once 
weekly for 6 weeks, in doses of 140, 175 and 200 mg/m2, 
respectively. No DLTs, SUSARs or SAEs occurred.
In each cohort, the minimum of three patients was 
included since radiotherapy and concomitant gemcitabine 
were well tolerated. No grade 4 or 5 laboratory toxicities 
were reported. Two patients showed laboratory grade 3 
hepatotoxicity: an increase in ALAT during their 6 weeks 
of treatment, up to 241 U/L in week 5, and 227 U/L in week 
6, respectively (normative value 0–35  U/L). Laboratory 
grade 2 and 3 neutropenia was observed in two patients. 
None of the aberrant values had consequences for the clini-
cal well-being of the patient, and all values normalized 
directly after treatment without any intervention. Therefore, 
no clinically relevant grade 3 toxicities were reported.
All patients experienced grade 2 nausea and vomiting 
during the 6-week treatment period. Therefore, ondan-
setron  (Zofran®) was administered intravenously before 
gemcitabine administration, and additional oral ondanse-
tron was administered if needed before radiotherapy. Nau-
sea and vomiting disappeared directly after treatment was 
completed. Local alopecia, restricted to the target area of Ta
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the radiation beam, was observed in all patients. Five out of 
nine patients experienced enhanced smell and altered taste 
during treatment, rated as grade 1 toxicity.
Efficacy
At diagnosis, clinical symptoms associated with DIPG 
such as ataxia, walking disturbances, and abducens nerve 
palsy resulting in diplopia were observed in most patients. 
Four out of nine patients received dexamethasone directly 
at time of diagnosis. Upon treatment, dexamethasone was 
tapered in three, and continued in one patient at a low dose 
(0.25  mg/day coming from 2 × 2  mg/day). One patient 
received a single dose of dexamethasone during treatment. 
In all patients, the clinical symptoms improved during 
treatment. No difference in clinical response was observed 
between the dose-level cohorts.
In the radiological response evaluation by the neuro-
radiologist at 3 months post-treatment, patients four and 
six had stable disease (SD), based on the modified RANO 
response criteria [15]. Two patients (patient three and 
nine) had progressive disease (PD) based on the occur-
rence of metastases. In the first, metastases spread dif-
fusely via the leptomeninges, infra- and supratentorial, 
along the spinal cord and intraventricular. In the sec-
ond, leptomeningeal spread was observed. Four patients 
showed a pattern fitting either progressive disease or 
pseudo-progression (PD/psPD). Upon clinical/radiologi-
cal follow-up, these patients (1, 2, 7, and 8) were retro-
spectively classified as having PD based on clinical and/
or further radiological progression. Finally, one patient 
showed PD within a month after finishing treatment with 
the occurrence of metastases (the MRI showed a metasta-
sis in the septum pellucidum and diffuse leptomeningeal 
spread), and died 1.5 months after treatment (no week 19 
scan was made). Supplementary Table 1 provides radio-
logic response assessments at baseline and 3  months 
post-treatment. No difference in radiological response 
was observed between the dose-level cohorts.
The median overall PFS and MOS of all nine patients 
were 4.8 months (95% CI 4.0–5.7) and 8.7 months (95% 
CI 7.0–10.4), respectively (Supplementary Fig.  1). 
According to the DIPG survival prediction model, our 
cohort included four intermediate- and five high-risk 
patients. PFS and MOS for intermediate-risk patients 
were 6.4 and 12.4 months, respectively, and for the high-
risk patients 4.5 and 8.1  months, respectively (Supple-
mentary Fig. 1). Figure 1 shows a detailed course of the 
disease for each patient. The median time from diagno-
sis to start of treatment was 18  days (range 8–28). One 
patient has not experienced disease progression and is 
alive at 34.2  months post-diagnosis (March 2017). No 
difference in survival was observed between the dose-
level cohorts.
Fig. 1  Detailed disease course for each patient included in this study. The frame marks the treatment period of 6 weeks
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Quality of Life
Table  2 contains total scores per questionnaire-category, 
and separate scores per subcategory within the question-
naire-categories. The higher the score, the better the QoL. 
All patients scored relatively high on all categories of the 
PedsQL TM 4.0 Generic Core Scales and the PedsQL TM 
Multidimensional Fatigue Scale questionnaires, except on 
the psychosocial health, which includes school absence. 
Although not statistically significant, all median scores of 
the PedsQL TM 4.0 Generic Core Scales questionnaire 
increased, suggesting a better quality of life after treatment. 
Furthermore, the PedsQL TM Multidimensional Fatigue 
Scale scores decreased after treatment. In the subcategories 
Table 2  Quality of Life 
assessment Median [IQR] P value (<0.05)
Week 0 Week 19
PedsQL TM 4.0 Generic Core Scales
 Self-report
  Physical performance 87.50 [37.50;96.88] 85.94 [64.06;93.75] 0.854
  Psychosocial health 85.00 [73.33;86.67] 87.50 [76.67;93.33] 0.273
  Total score 82.61 [60.87;86.96] 84.78 [74.46;93.48] 0.715
 Parent report
  Physical performance 78.13 [28.13;90.63] 82.81 [62.50;86.72] 0.715
  Psychosocial health 44.57 [42.39;54.35] 48.91 [46.47;49.73] 0.144
  Total score 44.57 [42.39;54.35] 48.91 [46.47;49.73] 0.144
PedsQL TM Multidimensional Fatigue Scale
 Self-report
  General score 75.00 [58.33;89.58] 83.33 [75.00;91.67] 0.713
  Sleep score 79.17 [56.25;97.92] 83.33 [70.83;93.75] 0.414
  Cognitive fatigue score 79.17 [66.67;100.00] 83.33 [62.50;97.92] 0.713
  Total score 81.94 [61.81;88.19] 81.94 [73.61;90.97] 0.500
 Parent report
  General score 66.67 [50.00;77.08] 87.50 [68.75;93.75] 0.273
  Sleep score 83.33 [54.17;93.75] 83.33 [83.33;95.83] 0.461
  Cognitive fatigue score 75.00 [56.25;89.58] 95.83 [77.08;97.92] 0.141
  Total score 81.94 [54.86;84.72] 86.11 [81.11;92.36] 0.080
PedsQL TM 3.0 Cancer Module
 Self-report
  Pain 100.00 [100.00;100.00] 100.00 [75.00;100.00] 0.157
  Nausea 100.00 [100.00;100.00] 80.00 [60.00;90.00] 0.042
  Fear of procedures 100.00 [100.00;100.00] 16.67 [4.17;50.00] 0.042
  Fear of treatment 100.00 [100.00;100.00] 75.00 [54.17;100.00] 0.109
  Worry 100.00 [100.00;100.00] 83.33 [75.00;100.00] 0.102
  Cognitive functioning 100.00 [100.00;100.00] 75.00 [50.00;100.00] 0.180
  Appearance 100.00 [100.00;100.00] 100.00 [87.50;100.00] 0.180
  Communication 100.00 [100.00;100.00] 83.33 [70.83;100.00] 0.180
  Total score 100.00 [100.00;100.00] 77.78 [69.44;80.56] 0.042
 Parent report
  Pain 100.00 [100.00;100.00] 100.00 [87.50;100.00] 0.317
  Nausea 95.00 [90.00;100.00] 65.00 [40.00;85.00] 0.104
  Fear of procedures 112.50 [75.00;150.00] 25.00 [00.00;87.50] 0.041
  Fear of treatment 100.00 [70.83;100.00] 75.00 [54.17;100.00] 0.109
  Worry 100.00 [87.50;100.00] 75.00 [75.00;100.00] 0.157
  Cognitive functioning 80.00 [77.50.00;84.38] 60.00 [55.63;75.00] 0.068
  Appearance 100.00 [87.50.00;100.00] 83.33 [75.00;95.83] 0.066
  Communication 100.00 [83.33.00;100.00] 100.00 [87.50;100.00] 0.18
  Total score 94.23 [86.57;96.71] 72.22 [68.32;81.02] 0.043
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of the PedsQL TM 3.0 Cancer Module questionnaire, nau-
sea and fear of procedure scored significantly lower after 
treatment compared to baseline. This resulted in a signifi-
cant decrease in the total score of the cancer questionnaire 
(P = 0.042). No difference in quality of life was observed 
between the dose-level cohorts.
Discussion
This phase I/II open-label single arm trial demonstrates that 
conventionally-fractionated radiotherapy (54  Gy), com-
bined with weekly gemcitabine in a dose up to 200 mg/m2/
week, is safe and well tolerated in children aged 7–17 years 
with newly-diagnosed DIPG. PFS and MOS were not dif-
ferent from historical control patients from equal risk-score 
cohorts. QoL tended to improve, but not to a statistically 
significant extent.
In previous studies in children, in which up to 18-fold 
higher doses of gemcitabine were given without radio-
therapy, myelotoxicity was reported, as well as eleva-
tion of liver enzymes and mucositis [8–11]. In our study, 
no DLTs, defined as clinically relevant grade 3 toxicities, 
were observed. During the 6-week treatment period, only 
decreased neutrophil counts and elevated ALAT were 
observed. These aberrant laboratory values all normalized 
directly after treatment and did not require treatment inter-
ruption or other medical management. By using the VMAT 
technique, toxicity of the irradiated mucosa was prevented 
and no mucositis was observed. All patients reported nau-
sea and vomiting, occurring directly after gemcitabine 
administration and during radiotherapy, which was consid-
ered the main disadvantage of participation in this study.
Efficacy, in terms of clinical and radiological response, 
PFS and MOS, was not different when compared to his-
torical control patients from equal risk-score cohorts. In 
patients with psPD, the clinical course of the patients 
provided the distinction between PD and psPD. Possi-
bly, radiologic responses could have been more conclu-
sive if successive MR-scans had been made with shorter 
time-intervals.
The overall PFS and MOS found in this study, were rela-
tively short (4.8 and 8.7  month, respectively) compared 
to survival data of DIPG patients receiving “radiotherapy 
only” found in literature (i.e. PFS of 6.0 months, MOS of 
10.0 months) [23]. This could be explained by the fact that 
all patients included in this study were either intermediate- 
(four) or high-risk (five) patients, when classified accord-
ing to the recently developed and validated DIPG survival 
prediction model [21, 22]. In the first study, intermedi-
ate- and high-risk DIPG patients showed a PFS of 7.0 and 
5.0  months, respectively (unpublished data), and a MOS 
of 9.7 and 7.0 months, respectively. It should be taken into 
account, however, that this cohort included patients that 
where treated with radiotherapy only, but also patients that 
received successive treatments after disease progression. 
Direct comparison of survival times might therefore not 
be reliable, but the observed difference between the risk-
groups is comparable in both studies and could be relevant 
in the interpretation of our results. Finally, in contrast to 
the relative short MOS of the total cohort, our study cohort 
includes two so-called long-term survivors (arbitrarily 
defined as patients who survive ≥24 months post-diagno-
sis). Both patients were typical DIPG patients based on 
their clinical symptoms and MR-imaging characteristics at 
time of diagnosis. Histology from biopsy of one of these 
patients showed WHO grade III anaplastic astrocytoma. 
Results of the other long-term survivor were, unfortunately, 
inconclusive and thus far repeat biopsy has not been per-
formed. The patient showing WHO grade II astrocytoma 
histology had a PFS of 6.4 months, in accordance with lit-
erature, and a relatively long OS of 19.1 months. Since it 
is well known that DIPGs are heterogeneous tumors [24], 
with areas varying from low (WHO grade II) to high-grade 
(WHO grade III and IV) tumors, we did not take histology 
into account in the interpretation of our results. Moreover, 
WHO grade II–IV was previously found not to correlate 
with survival in DIPG [25]. Determination of histone muta-
tion status would be of interest, but is not known for the 
patients included in this study, as the analysis was not read-
ily available when the study was designed in 2012. How-
ever, the prolonged survival (i.e. >18 months) of three (out 
of nine) patients might be caused by a different underlying 
tumor biology. To conclude, with the current study design 
with limited patient numbers, it cannot be determined 
whether the prolonged survival of these patients is a result 
of the treatment itself, or influenced by the underlying bio-
logical background of their tumors.
Current knowledge about the BBB in DIPG suggests 
that gemcitabine has limited BBB passage. However, as 
radiotherapy has been shown to temporarily disrupt the 
BBB, administration of gemcitabine is expected to be more 
efficient and effective during radiotherapy [26]. Based 
on recent studies, dosages up to 750 mg/m2 can safely be 
explored in future gemcitabine-radiotherapy studies [27]. 
Potentially gemcitabine dosing in combination with radio-
therapy can be escalated even further, as in children dose 
limiting toxicities of gemcitabine monotherapy were only 
observed at doses as high as 3600 mg/m2. Since these DLTs 
were mainly hepatotoxicity and hematological toxicity, it is 
unlikely that local radiotherapy to the brainstem will aggra-
vate or increase the incidence of these DLTs.
In vitro studies have described a decreased activity of 
gemcitabine when combined with dexamethasone [19, 
20]. Unfortunately, due to the limited number of patients 
enrolled in this study and the different treatment schedules 
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used, it is not possible to determine whether dexamethasone 
use in the current study affected the outcome. Of specific 
note, in four out of nine patients, including one of the long-
term survivors, no dexamethasone was given at diagnosis 
or during chemo-radiotherapy, and the other long-term 
survivor used only a single dose of dexamethasone during 
treatment. This indicates that corticosteroids may not be a 
stringent necessity in newly diagnosed DIPG patients.
In the assessment of QoL in DIPG patients under treat-
ment, our study showed remarkably low scores for psy-
chosocial health compared to the other scores assessed 
in this study. This could be attributed to the fact that one 
question assesses school absence, and due to the intensive 
treatment schedule most children did not attend school dur-
ing the 6-week treatment period. The observed decrease in 
the PedsQL TM 3.0 Cancer Module questionnaire scores 
might partly be explained by nausea, being the main side 
effect of this treatment. Off note, to reduce edema and to 
control nausea during radiotherapy, dexamethasone is com-
monly used in DIPG patients. In this study, however, the 
use of dexamethasone was limited because of the possi-
ble drug-interaction with gemcitabine, its negative effects 
on blood–brain–barrier passage of drugs [19, 20] and its 
well-known side effects [18]. Instead, nausea was treated 
with ondansetron  (Zofran®). The observed mild decrease 
in the PedsQL TM 3.0 Cancer Module questionnaire 
scores might furthermore be influenced by anxiety around 
the weekly placement of the IV cannula for the infusion 
of gemcitabine. In future trials this could be prevented by 
placement of a central line. Unfortunately, no historical 
data on QoL are available for DIPG patients. Neverthe-
less, all patients and parents evaluated participation in this 
study as a positive experience. Even though this treatment 
had a great impact on a family’s daily routine for 6 weeks, 
none of the parents or patients experienced a significant 
burden from the procedures. Instead, families reported to 
have experienced support from the intensive level of sup-
port and care from the treating physician and the research 
team. A limitation of the QoL evaluation in this study is 
that QoL was only measured at two time points (baseline 
and 3  months after treatment), while longer follow-up 
could have provided more information. In the design of the 
study we took into account the burden these questionnaires 
might have, the duration of administration of the study drug 
(i.e. 6  weeks), and the short survival of DIPG patients. 
Recently, Mandrell et al. were the first to demonstrate that 
frequent evaluation and follow-up of QoL is feasible in 
DIPG patients [28]. Unfortunately, in that study other types 
of PedsQL questionnaires were used. Therefore, no one-on-
one comparison could be made with the results found in 
our current study.
In conclusion, this study demonstrates that weekly 
gemcitabine concomitant to radiotherapy is safe and well 
tolerated in doses up to 200  mg/m2 in children suffer-
ing from newly diagnosed DIPG. Because of the limited 
number of patients included in this study, and the limited 
knowledge on the biology of each patient’s tumor, no defi-
nite conclusions on the preliminary efficacy can be drawn. 
Based on promising results from recent studies in adult 
glioblastoma [27], a study to assess the safety, tolerability 
and efficacy of higher doses of gemcitabine, in combination 
with radiotherapy, is being prepared. Furthermore, inves-
tigating the safety, tolerability and efficacy of the use of 
gemcitabine concurrently as a radiosensitizer and adjuvant 
as a cytotoxic therapy could be of interest.
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